• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Marijuana Vape-Tech Company Doing Business With Celebs Announces $12.3M Public Share Offering

    3/22/24 12:23:48 PM ET
    $HPCO
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $HPCO alert in real time by email

    Ispire Technology Inc. (NASDAQ:ISPR), a maker of e-cigarettes and cannabis vaping products, announced on Friday the pricing of a public offering of 2.05 million shares of common stock for $6 per share for gross proceeds of $12.3 million.

    The Los Angeles-based company said in a press release the closing of the offering is expected to take place on or about Tuesday, March 26.

    Ispire said it plans to use the net proceeds of the offering in connection with the establishment and operation of its manufacturing facility in Malaysia, funding of its joint venture with Touch Point Worldwide Inc., which does business as Berify and Chemular Inc., and working capital and general corporate purposes, including research and development.

    Roth Capital Partners acted as the lead placement agent for the offering. TFI Securities and Futures Limited acted as co-placement agent for the offering.

    Michael Wang, the company’s CEO, shared his valuable business insights at September’s cannabis Benzinga event. Benzinga Cannabis Capital Conference returns to Florida this April, 16-17.

    Pro-tip for Benzinga readers: Secure your tickets for the conference ASAP. Prices will increase very soon! You can get a 20% discount on tickets following this link right now.

    Cannabis Is Fueling Ispire's Growth

    Meanwhile, the company’s cannabis business vertical has been driving Ispire's profits for several quarters.

    Ispire recently reported a 30.7% year-over-year increase in revenue to $41.7 million in the second quarter. Cannabis vaping products contributed $19.5 million to total revenue, representing a 149% year-over-year increase, while tobacco vaping products contributed $22.1 million.

    First-quarter financial results published in late 2023 showed cannabis vaping products contributed $17.3 million to total quarterly revenue, up by 116.8% year-over-year, while tobacco vaping products contributed $25.5 million, representing a 34.8% year-over-year increase.

    Moreover, the company is backing celebrities like Snoop Dogg and GRAMMY-Award winner Damini Ebunoluwa Ogulu, a.k.a. Burna Boy, who are now established names in the cannabis space.

    This past December Ispire's Aspire North America, LLC., entered a five-year exclusive global manufacturing and distribution agreement with BrkFst, a lifestyle brand by Burna Boy, and his inner circle of young entrepreneurs.

    Hempacco Co., Inc. (NASDAQ:HPCO), a manufacturer of hemp-based alternatives, cannabinoid smokables and rolling papers and a subsidiary of Green Globe International Inc. also landed a five-year exclusive manufacturing and global distribution agreement with Ispire's subsidiary last year.

    Under the agreement, Aspire will distribute and commercialize Hempacco's branded cannabinoid and nicotine vapor products, namely Dogg Lbs by Snoop Dogg.

    ISPR Price Action

    Ispire's shares traded 27.91% lower at $5.85 per share at the time of writing on Friday morning.

    The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

    Get your tickets now on bzcannabis.com – Prices will increase very soon!

    Get the next $HPCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HPCO
    $ISPR

    CompanyDatePrice TargetRatingAnalyst
    Ispire Technology Inc.
    $ISPR
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $HPCO
    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $HPCO
    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $HPCO
    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $29,592 worth of shares (9,000 units at $3.29), decreasing direct ownership by 2% to 390,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/17/26 5:53:18 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $HPCO
    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

    LOS ANGELES, March 11, 2026 /PRNewswire/ -- Ispire Technology Inc. ((ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Ispire's management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026. 38th Annual ROTH ConferenceDate: March 22-24, 2026Location: Dana Point, CaliforniaFireside Chat Details: Monday, March 23, 2026, at 8:00 a.m. PT in Blue-Consumer-Salon 2To schedule a one-on-one meeting with the Company's management team, please

    3/11/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions

    Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions.

    2/4/26 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $HPCO
    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $HPCO
    $ISPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $HPCO
    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $HPCO
    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care